A recent Phase 1 single ascending Dose study found that PRX005 was a safe and effective treatment for Alzheimer’s disease, according to a press release from Prothena.
PRX005 is a tri-epitopic antibody that binds with high affinity to the R1, R2, and R3 repeats within the microtubule binding region of tau and targets 3R and 4R isoforms.
In the study, healthy volunteers were enrolled into three PRX005 dose level cohorts: low, medium or high dose. The study found that all three dose levels were safe and well tolerated.
“We developed PRX005 to uniquely target a key region within the MTBR